NCT07748403 — "A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)" trial site landscape

Public-registry site landscape for NCT07748403, “A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)”, a Wilson Disease study sponsored by Prime Medicine, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT07748403 (registry record)
Study title	A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)
Official title	A Phase 1/2 Clinical Study to Evaluate Safety, Tolerability, Biological Activity, and Initial Efficacy of Prime Editing (PM577a) for the Treatment of Wilson Disease (WD) in Adult and Adolescent Participants With at Least One Allele Harboring the p.H1069Q Mutation in ATP7B
Sponsor	Prime Medicine, Inc.
Condition(s)	Wilson Disease; Wilson's Disease; Wilsons Disease
Phase	PHASE1 / PHASE2
Listed sites	1
Site countries	New Zealand

Patient-friendly overview of this study: eichor.com/study/NCT07748403.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT07748403 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →